Progentec Gains Additional Funding for Lupus Detection and Management Platforms

By sarah | News | 0 comment | 8 December, 2018 | 0

By Mary Chapman
Lupus News Today
Copyright © 2013-2018 All rights reserved.

Completion of a second round of funding could help bring closer to market Progentec Diagnostics‘ new tool for predicting lupus flares and a biomarker-based index that monitors underlying disease activity.

Funding for Progentec’s biomarker-based diagnostic testing was led by venture capital outfits i2E and OCA Ventures, with participation by global healthcare provider NMC Lifesciences. Using technology created by the Oklahoma Medical Research Foundation, the platform is touted as being able to detect impending flares and track underlying disease movement.

“Today’s funding round is the next step on our journey to making this and other advanced tools commercially available to patients with lupus, a disease that afflicts more than one million Americans, many of whom are women,” Mohan Purushothaman, PhD, Progentec’s CEO, said in a press release. “The Progentec tests will become powerful tools to help patients and healthcare providers stay ahead of lupus.”

Read the entire story at Lupus News Today

Lupus News Today, Mohan Purushothaman, Progentec Diagnostics

Linear Health Sciences Announces U.S. FDA Clearance and Health Canada Approval of its Orchid Safety Release Valve (SRV)

By sarah | Comments are Closed

Device Intended to Reduce Risk of IV Catheter Failure and Replacement in Hospitals; Sister Product Orchid SRV-Type D for Drainage to Launch Simultaneously OKLAHOMA CITY, Okla. – May 17, 2022 – Medical device company LinearRead more
Student teams from OSU, TU and East Central claim Love’s Cup top awards

By sarah | Comments are Closed

May 3, 2022 Contact: Sarah Seagraves, Senior VP for Marketing (405) 813-2403 or email sseagraves@i2E.org Teams led by student innovators from Oklahoma State University, the University of Tulsa and East Central University claimed first placeRead more
A final column and a thank you for reading

By sarah | Comments are Closed

Thank you for reading this column for nearly a decade By Scott Meacham This is my final column for The Oklahoman. As CEO of i2E, I have had the wonderful opportunity since January 2013 to write thisRead more
A significant impact on new ventures? That’s i2E’s e3 program

By sarah | Comments are Closed

Accelerators like i2E’s e3 can have a significant impact on new ventures By Scott Meacham When the team from Zen Health Technologies formally introduces their company, they describe a business that uses immersive technologies for personalRead more
Autigen Announces Collaboration with Boehringer Ingelheim

By sarah | 0 comment

Novel Treatments for Hearing Loss Collaboration and licensing agreement to advance novel therapies for sensorineural hearing loss (SNHL), where there are currently no approved pharmacological therapies. OKLAHOMA CITY–(BUSINESS WIRE)– Autigen, a biotechnology portfolio company of theRead more

You must be logged in to post a comment.

Next Previous

Progentec Gains Additional Funding for Lupus Detection and Management Platforms

Progentec Gains Additional Funding for Lupus Detection and Management Platforms

Related Post

Linear Health Sciences Announces U.S. FDA Clearance and Health Canada Approval of its Orchid Safety Release Valve (SRV)

Student teams from OSU, TU and East Central claim Love’s Cup top awards

A final column and a thank you for reading

A significant impact on new ventures? That’s i2E’s e3 program

Autigen Announces Collaboration with Boehringer Ingelheim

Leave a Comment

Oklahoma City Office

Tulsa Office